| BACKGROUND
Influenza's ability to antigenically drift imposes the constant need for an update to the annual World Health Organization's (WHO) recommended vaccine composition for both the Northern Hemisphere and Southern Hemisphere (NH and SH). The WHO's recommended vaccine composition includes three strains of influenza virus: two influenza A and one influenza B.
1 The variable level of putative cross-protection that can be obtained from nonmatching circulating strains 2 allows for some protection even when the vaccine compositions do not match circulating viruses.
Yet, the proportion of circulating influenza viruses in the epidemic period after vaccination that matches with the recommended vaccine composition is not a metric used to measure potential vaccine protection.
Tropical countries have a much more complex circulation pattern of influenza 3, 4 as they are frequently out of phase with the dynamics predicted for their hemispheric group. Several studies have assessed the best recommended vaccine composition mainly for the Southern
Hemisphere. [4] [5] [6] [7] [8] [9] Studies by Mello et al, 5 Waiboci et al, 9 Alonso et al 10 and Mah-E-Muneer et al 11 used a method to measure the proportion of circulating influenza viruses in the epidemic period after vaccination that matched with the recommended vaccine compositions in tropical countries. Although not the objective and not discussed in the above studies, by reviewing their data we observed that their rates of vaccine matching were low (below 50%). This raises concerns about vaccine protection and implementation of successful immunization programmes.
Madagascar is unique as it is an island located in the tropical belt of the Southern Hemisphere. It has a tropical climate with two different seasons: hot and humid from November to April, and cool and dry from May to October. However, larger climatic variations are encountered within the island. Madagascar has a robust influenza surveillance system, and the absence of an influenza national vaccination programme provided an opportunity to investigate the importance of vaccine matching to circulating strains. In Madagascar, influenza vaccine is available only at some private institutions (eg, Institut Pasteur de Madagascar) and is not widely available to the general population.
Additionally, these analyses may assist Malagasy health authorities to identify the optimal timing and vaccine formulation in the event a population-wide routine influenza immunization programme is implemented.
| METHODS

| Influenza strain characterization
Madagascar has an effective clinical and virological influenza surveillance system allowing for robust multi-year epidemiological studies. [12] [13] [14] 
| Matching of vaccine strains according to different scenarios, 2002-2014
The method used to evaluate and compare alternative vaccination recommendations both in terms of time and composition (NH vs SH) was developed by one of the authors (WJA) and described elsewhere. 5 In brief, we analysed the hypothetical matching success that each hemispheric WHO's influenza recommended vaccine composition (Table   S1) Malagasy influenza B strains were matched with vaccine strains if they belonged to the same lineage and were antigenically similar to the vaccine strain in the HI assay.
Next, the vaccine match for each year and in total was estimated, according to six vaccine delivery scenarios:
1. Scenario Zero: No lag from the time that the vaccine was available for both NH (October) and SH (April) recommendations; 
| Statistical analysis
Global comparison between WHO's NH and SH recommended vaccine composition scenarios was performed by comparing matching proportions at each delivery lag (zero to 5 months) independently. To allow all years to contribute equally in the analyses, the grand total proportion of matching success was the average of the matching success of each year. Differences in proportions were assessed in chisquared tests using Stata Statistical Software: Release 13 (StataCorp LP, College Station, TX, USA). Values of P < .05 were considered significant.
| RESULTS
| Detection of influenza strains
The 78 Figure 2 illustrates the analyses performed for the NH and SH vaccines for only one hypothetical scenario for each hemispheric recommended vaccine composition: if vaccines were delivered as soon as available after the WHO's recommendations were issued. Table 1 and Figure S1 show the number and proportion of detected viruses of the final data set that hypothetically matched with either NH or SH recommended vaccine strains per year. When no lag in vaccine delivery was considered (central columns of the Table S3 ).
| Matching success of both vaccine strategies (NH vs SH) without vaccine delivery delay
| Matching success according to different vaccine delay scenarios
Results of analyses utilizing delays of 1-5 months are summarized in Table 1 and Figure S1 . Matching success was year-dependent, but no specific pattern emerged. However, large variations in rates of successful matching were observed and ranged from zero to 100%.
For a delay of up to 3 months, matching success was slightly higher for the NH recommendations than for the SH (36% and 34%, respectively). Further with a delay of up to 5 months, the SH recommendation (42%) was a slightly more successful match than for the NH (36%). Our assessment may appear applicable only to Madagascar due to its erratic influenza viral circulation pattern. 7 However, we found that
| DISCUSSION
Matching success of recommended vaccine strains against influenza viruses isolated monthly in Madagascar. Blue and red lines correspond, respectively, to WHO's NH and SH vaccine recommendations and schedule (assumed 9 subsequent months of immunity protection). The rate of successful matches between the vaccines and circulating influenza strains is quantified by the overlap between the simulated vaccine immunization period (blue or red) and actual virus isolations (green diamonds) through this period. Diamonds represent a single detection per month, with exception of the darker one which represent two detections in that month (Fig. 1) low successful strain match between WHO's recommended vaccination compositions and circulating viruses is a constant, not an exception as based on a review of the data from studies that investigated the proportion of influenza strain matching and which took into account the timing of vaccine delivery. 4, 5, 9, 11 Successful matching between NH and SH recommended vaccine strains and circulating viruses was reported at 39% and 40% in Bangladesh; 11 53.6% and 46.4% in Kenya; 9 18% and 35% 5 and less than 30% and 20% for H3N2 4 in Brazil. In temperate areas, studies focused mainly on influenza vaccine effectiveness (VE) solely. However, some previous works [22] [23] [24] including also antigenic match data highlighted that vaccine mismatch can strongly impact on VE despite substantial cross-protection. They suggested that antigenic characterization data should be included in VE estimates studies.
Our sample size might appear as a possible limitation of this study with 78 viruses over a period of 12 years. Our study is based on retrospective analyses on data obtained for other purposes (the global efforts of influenza surveillance for assisting the formulation of the vaccine by the WHO). Still, it is important to note that our sample size is double the number presented by the study that triggered the current WHO's attention on the problem of the vaccine composition and timing in the tropics. 5 Regarding the optimal timing of influenza vaccination and the optimal composition recommendation to be adopted, our study showed has not been previously discussed or studied in depth. We believe that this is a key factor, which needs to be considered for inclusion in costeffectiveness analyses of national immunization programmes. The vaccination matching for each year (% in parenthesis) and in total, considered that no lag would exist from the time that the vaccine was made available for each hemisphere (two columns in the centre) and time lags of up to 1, 2, 3, 4 and 5 months (eg, due to logistical problems). Blue and red colours correspond, respectively, to WHO's NH and SH vaccine recommendations and schedules.
